NRx Gets FDA Expanded Access for Ketamine Protocol

FDA Clears a Wider Path for NRx's Ketamine-Based Treatment

On June 22, 2026, NRx Pharmaceuticals announced that the U.S. Food and Drug Administration has granted Expanded Access — sometimes called compassionate use — for its ketamine-based treatment protocol, according to a GlobeNewswire release. For patients and providers tracking the evolution of ketamine medicine, this is a meaningful regulatory development — one that could open access to an investigational protocol for qualifying patients who currently have no comparable treatment options.

The FDA's Expanded Access program is a formal pathway that allows patients with serious or life-threatening conditions to receive investigational drugs outside of a completed clinical trial. Expanded Access is not the same as full FDA approval. Rather, it reflects the agency's determination that preliminary safety and efficacy data are sufficient to justify access for certain patients, often while a company continues its path toward standard approval. The FDA evaluates each application individually, and a grant signals that the benefit-risk balance appears favorable for the proposed patient population.

What NRx Pharmaceuticals Has Been Working On

NRx Pharmaceuticals has spent several years developing a sequential treatment protocol targeting suicidal ideation in patients with Bipolar I disorder — one of the most treatment-resistant and high-risk conditions in psychiatry. Their approach combines an initial course of intravenous ketamine, which the company's research has used to rapidly reduce acute suicidality, with a follow-on oral maintenance treatment called NRX-101, a fixed-dose combination of d-cycloserine and lurasidone designed to sustain stabilization after ketamine's effects subside.

This pairing addresses a well-documented clinical gap. IV ketamine can produce rapid and dramatic reductions in suicidal ideation, sometimes within hours or days. But its effects are typically short-lived, and the question of how to extend remission in acutely suicidal patients has been one of the central challenges in this field. NRx's protocol attempts to use ketamine as a stabilizing bridge, then transition patients to an oral agent that can be maintained over time.

The FDA Expanded Access grant suggests the agency is satisfied enough with NRx's cumulative data — from preclinical work through clinical trials — to allow this protocol to reach patients outside of a trial setting, at least on a limited basis. That is a significant threshold. Companies do not receive Expanded Access for protocols the FDA considers unsafe or insufficiently supported by evidence.

Why This Matters for the Broader Ketamine Treatment Landscape

For the ketamine medicine community, this announcement arrives at a time of increased regulatory attention and evolving standards of care. The 2023 DEA and FDA actions around telehealth prescribing of controlled substances tightened the conditions under which ketamine — a Schedule III controlled substance — can be prescribed remotely. Against that backdrop, a formal FDA Expanded Access designation for a structured, hospital- or clinic-based ketamine protocol moves in a different direction: it expands access, but within a defined clinical framework that includes oversight, monitoring, and a documented benefit-risk rationale.

This distinction matters to patients evaluating their options. Ketamine therapy in the United States currently spans a wide spectrum. At one end are established outpatient infusion clinics and telehealth providers offering compounded oral or sublingual ketamine under the DEA prescribing rules. At the other end are FDA-approved products like esketamine nasal spray (Spravato), which carries full regulatory clearance for treatment-resistant depression and major depressive disorder with suicidal ideation. NRx's protocol, if it eventually receives full approval, would occupy a distinct niche: a sequential IV-to-oral protocol for one of psychiatry's hardest-to-treat populations.

Expanded Access itself does not automatically mean a treatment will become broadly available. Programs are typically limited to specific patient criteria, designated treatment centers, and ongoing safety monitoring. Patients hoping to access the NRx protocol through Expanded Access would likely need to meet specific diagnostic criteria, have failed prior treatments, and be treated at sites participating in the program. This is not a pathway that will immediately affect most people searching for ketamine therapy online.

What Patients Should Watch and Do Next

The NRx Expanded Access grant is worth tracking for two reasons. First, it adds to the body of regulatory signals that ketamine-adjacent treatments for acute suicidality are moving through formal FDA channels — suggesting this therapeutic area is maturing toward more structured, evidence-backed protocols. Second, if NRx eventually pursues and receives full FDA approval, it could expand the covered treatment options available to patients whose insurance currently does not reimburse off-label IV ketamine infusions.

For patients currently considering ketamine treatment — whether through a telehealth provider, an outpatient clinic, or a psychiatrist's office — this announcement is background context, not an immediate action item. What it reinforces is that the ketamine treatment field is not static. Regulatory frameworks, approved indications, and available protocols continue to evolve. That makes provider selection and ongoing follow-up care more important, not less: patients benefit most from providers who stay current with the clinical evidence and can help them navigate a changing landscape.

If you or someone you know is experiencing suicidal ideation, contact the 988 Suicide and Crisis Lifeline by calling or texting 988. This news analysis is for informational purposes and does not constitute medical advice.